Clinical Trials

600 enrolled

Carcinoma, Hepatocellular, Liver Cirrhosis, Sarcopenia

NCT07293468 2025-12-19

BIIRTH

Phase 2/3 Recruiting

106 enrolled

Carcinoma, Hepatocellular

NCT05971108 2025-09-24

REVISE-HCC

600 enrolled

Fibrosis, Carcinoma, Hepatocellular, Liver Cirrhosis

NCT07170345 2025-09-12

HCC-MVI-CAD

400 enrolled

Carcinoma, Hepatocellular

NCT07150624 2025-09-02

The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine

Phase 4 Recruiting

96 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Hepatocellular, Liver Diseases

NCT03093688 2025-07-02

Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor

Phase 1/2 Recruiting

40 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT05623150 2025-03-13

CHALNA2

710 enrolled

Carcinoma, Hepatocellular, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease

NCT06594744 2025-02-13

P-HCC-CVL

Phase 4 Recruiting

120 enrolled

Esophageal and Gastric Varices, Carcinoma, Hepatocellular, Hypertension, Portal

NCT06498622 2024-07-12

Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

Phase 2 Recruiting

45 enrolled

Carcinoma, Hepatocellular

NCT06478927 2024-06-27

Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib

22 enrolled

Carcinoma, Hepatocellular

NCT06384950 2024-04-25

Evaluating the Role of ChatGPT in Educating Patients With Early-stage Hepatocellular Carcinoma

450 enrolled

Carcinoma, Hepatocellular

NCT05047510 2023-08-30

GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma

60 enrolled

Carcinoma, Hepatocellular

NCT05502198 2023-08-24

ACCESS-ESLD

150 enrolled

Carcinoma, Hepatocellular, Hypertension, Portal, Liver Cirrhosis, Sarcopenia

NCT05407519 2023-03-22

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Phase 2 Recruiting

40 enrolled

Carcinoma, Hepatocellular

NCT05738980 2023-02-22

Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3

88 enrolled